Single-dose pharmacokinetics of orally administered terbinafine in bearded dragons (Pogona vitticeps) and the antifungal susceptibility patterns of Nannizziopsis guarroi.

OBJECTIVE To identify the antifungal susceptibility of Nanniziopsis guarroi isolates and to evaluate the single-dose pharmacokinetics of orally administered terbinafine in bearded dragons. ANIMALS 8 healthy adult bearded dragons. PROCEDURES 4 isolates of N guarroi were tested for antifungal susceptibility. A compounded oral solution of terbinafine (25 mg/mL [20 mg/kg]) was given before blood (0.2 mL) was drawn from the ventral tail vein at 0, 4, 8, 12, 24, 48, 72, and 96 hours after administration. Plasma terbinafine concentrations were measured with high-performance liquid chromatography. RESULTS The antifungal minimum inhibitory concentrations against N guarroi isolates ranged from 4,000 to > 64,000 ng/mL for fluconazole, 125 to 2,000 ng/mL for itraconazole, 125 to 2,000 ng/mL for ketoconazole, 125 to 1,000 ng/mL for posaconazole, 60 to 250 ng/mL for voriconazole, and 15 to 30 ng/mL for terbinafine. The mean ± SD peak plasma terbinafine concentration in bearded dragons was 435 ± 338 ng/mL at 13 ± 4.66 hours after administration. Plasma concentrations remained > 30 ng/mL for > 24 hours in all bearded dragons and for > 48 hours in 6 of 8 bearded dragons. Mean ± SD terminal half-life following oral administration was 21.2 ± 12.40 hours. CLINICAL RELEVANCE Antifungal susceptibility data are available for use in clinical decision making. Results indicated that administration of terbinafine (20 mg/kg, PO, q 24 to 48 h) in bearded dragons may be appropriate for the treatment of dermatomycoses caused by N guarroi. Clinical studies are needed to determine the efficacy of such treatment.

[1]  S. Jaensch,et al.  Haematology and plasma biochemistry reference intervals in wild bearded dragons (Pogona vitticeps). , 2021, Australian veterinary journal.

[2]  A. Miller,et al.  Emydomyces testavorans, a New Genus and Species of Onygenalean Fungus Isolated from Shell Lesions of Freshwater Aquatic Turtles , 2018, Journal of Clinical Microbiology.

[3]  M. Allender,et al.  Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus). , 2017, Journal of veterinary pharmacology and therapeutics.

[4]  E. Driskell,et al.  PHARMACOKINETICS, EFFICACY, AND SAFETY OF VORICONAZOLE AND ITRACONAZOLE IN HEALTHY COTTONMOUTHS (AGKISTRODON PISCIVORUS) AND MASSASAUGA RATTLESNAKES (SISTRURUS CATENATUS) WITH SNAKE FUNGAL DISEASE , 2017, Journal of Zoo and Wildlife Medicine.

[5]  P. Redig,et al.  Plasma Concentrations of Itraconazole, Voriconazole, and Terbinafine When Delivered by an Impregnated, Subcutaneous Implant in Japanese Quail (Coturnix japonica) , 2017, Journal of Avian Medicine and Surgery.

[6]  D. Reeder,et al.  Pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans. , 2017, American journal of veterinary research.

[7]  Nicholas A. Crossland,et al.  Nannizziopsis guarroi infection in 2 Inland Bearded Dragons (Pogona vitticeps): clinical, cytologic, histologic, and ultrastructural aspects. , 2016, Veterinary clinical pathology.

[8]  J. Paré,et al.  An Overview of Reptile Fungal Pathogens in the Genera Nannizziopsis, Paranannizziopsis, and Ophidiomyces , 2016 .

[9]  I. Loncaric,et al.  Dermatomycosis in three central bearded dragons (Pogona vitticeps) associated with Nannizziopsis chlamydospora , 2016, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[10]  Amelia G. White,et al.  Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. , 2015, Veterinary dermatology.

[11]  J. Yarbrough,et al.  Determining Terbinafine in Plasma and Saline Using HPLC , 2015 .

[12]  J. Guarro,et al.  Chrysosporium-Related Fungi and Reptiles: A Fatal Attraction , 2014, PLoS pathogens.

[13]  P. Parejiya,et al.  Drug delivery to the nail: therapeutic options and challenges for onychomycosis. , 2014, Critical reviews in therapeutic drug carrier systems.

[14]  M. Walden,et al.  Chrysosporium anamorph Nannizziopsis vriesii: an emerging fungal pathogen of captive and wild reptiles. , 2013, The veterinary clinics of North America. Exotic animal practice.

[15]  S. Hambleton,et al.  Molecular Characterization of Reptile Pathogens Currently Known as Members of the Chrysosporium Anamorph of Nannizziopsis vriesii Complex and Relationship with Some Human-Associated Isolates , 2013, Journal of Clinical Microbiology.

[16]  J. Guarro,et al.  Phylogeny of chrysosporia infecting reptiles: proposal of the new family Nannizziopsiaceae and five new species , 2013, Persoonia.

[17]  E. E. Evans,et al.  Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). , 2013, American journal of veterinary research.

[18]  M. Garbelotto,et al.  Back to basics: an evaluation of NaOH and alternative rapid DNA extraction protocols for DNA barcoding, genotyping, and disease diagnostics from fungal and oomycete samples , 2013, Molecular ecology resources.

[19]  M. Souza,et al.  Pharmacokinetics of nebulized terbinafine in Hispaniolan Amazon parrots (Amazona ventralis). , 2012, Journal of avian medicine and surgery.

[20]  P. Raiti.  Husbandry, Diseases, and Veterinary Care of the Bearded Dragon (Pogona vitticeps) , 2012 .

[21]  K. Keller.  Therapeutic Review: Terbinafine , 2012 .

[22]  Z. Zeng,et al.  Single dose pharmacokinetics of terbinafine in cats , 2012, Journal of feline medicine and surgery.

[23]  T. Day,et al.  Terbinafine pharmacokinetics after single dose oral administration in the dog. , 2011, Veterinary dermatology.

[24]  S. Hambleton,et al.  Deep fungal dermatitis caused by the Chrysosporium anamorph of Nannizziopsis vriesii in captive coastal bearded dragons (Pogona barbata). , 2011, Australian veterinary journal.

[25]  B. Kukanich,et al.  Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. , 2011, Journal of veterinary pharmacology and therapeutics.

[26]  P. de Backer,et al.  Voriconazole, a safe alternative for treating infections caused by the Chrysosporium anamorph of Nannizziopsis vriesii in bearded dragons (Pogona vitticeps). , 2010, Medical mycology.

[27]  R. Poppenga,et al.  Pharmacokinetics of Terbinafine After Single Oral Dose Administration in Red-Tailed Hawks (Buteo jamaicensis) , 2010, Journal of avian medicine and surgery.

[28]  R. Poppenga,et al.  Pharmacokinetics of Orally Administered Terbinafine in African Penguins (Spheniscus demersus) for Potential Treatment of Aspergillosis , 2010, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[29]  S. Krishnan-Natesan.  Terbinafine: a pharmacological and clinical review , 2009, Expert opinion on pharmacotherapy.

[30]  A. Ramis,et al.  Dermatomycosis in a pet inland bearded dragon (Pogona vitticeps) caused by a Chrysosporium species related to Nannizziopsis vriesii. , 2009, Veterinary dermatology.

[31]  R. Marsella,et al.  Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy. , 2007, Veterinary dermatology.

[32]  K. Sladky,et al.  Deep fungal dermatitis in three inland bearded dragons (Pogona vitticeps) caused by the Chrysosporium anamorph of Nannizziopsis vriesii. , 2007, Medical mycology.

[33]  P. Toutain,et al.  The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. , 2002, Research in veterinary science.

[34]  A. McLachlan,et al.  Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans , 2002, Antimicrobial Agents and Chemotherapy.

[35]  Sanjeev Jain,et al.  Terbinafine, a unique oral antifungal: current perceptions , 2000, International journal of dermatology.

[36]  M. Nahata,et al.  Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[37]  J. Nedelman,et al.  The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. , 1997, Biopharmaceutics & drug disposition.

[38]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. , 1993, Acta dermato-venereologica.

[39]  J. Jensen.  Pharmacokinetics of Lamisil® in humans , 1990 .